Your browser is no longer supported. Please, upgrade your browser.
KIN Kindred Biosciences, Inc. daily Stock Chart
Kindred Biosciences, Inc.
Index- P/E- EPS (ttm)-1.75 Insider Own5.40% Shs Outstand39.19M Perf Week-6.71%
Market Cap165.68M Forward P/E- EPS next Y-1.03 Insider Trans-4.77% Shs Float36.90M Perf Month-25.48%
Income-68.10M PEG- EPS next Q0.00 Inst Own67.70% Short Float1.30% Perf Quarter-6.04%
Sales4.30M P/S38.53 EPS this Y0.90% Inst Trans0.96% Short Ratio1.13 Perf Half Y-60.39%
Book/sh1.55 P/B2.51 EPS next Y18.40% ROA-60.60% Target Price- Perf Year-50.95%
Cash/sh1.26 P/C3.10 EPS next 5Y40.00% ROE-78.70% 52W Range3.11 - 11.93 Perf YTD-54.13%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-61.80% 52W High-67.39% Beta1.04
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin86.70% 52W Low25.28% ATR0.40
Employees156 Current Ratio5.70 Sales Q/Q20.00% Oper. Margin- RSI (14)38.68 Volatility7.79% 10.24%
OptionableYes Debt/Eq0.32 EPS Q/Q-36.70% Profit Margin- Rel Volume0.44 Prev Close3.98
ShortableYes LT Debt/Eq0.32 EarningsMay 07 AMC Payout- Avg Volume423.83K Price3.89
Recom2.00 SMA20-8.97% SMA50-15.46% SMA200-43.11% Volume188,200 Change-2.26%
Mar-17-20Downgrade Guggenheim Buy → Neutral
Nov-13-19Reiterated H.C. Wainwright Buy $17.50 → $16
Jul-16-19Downgrade B. Riley FBR Buy → Neutral $18 → $8.50
Jun-11-19Initiated Barclays Overweight $13
May-23-19Initiated Stifel Buy
May-23-19Initiated Guggenheim Buy $11
Mar-07-19Reiterated Lake Street Buy $30 → $12
Nov-08-18Reiterated B. Riley FBR Buy $16 → $21
Jul-24-18Initiated Cantor Fitzgerald Overweight
Dec-27-17Initiated CL King Neutral
Nov-20-17Resumed B. Riley FBR, Inc. Buy $11
Nov-17-17Initiated H.C. Wainwright Buy $9.50
May-24-17Initiated FBR & Co. Outperform $10
Nov-01-16Initiated Ladenburg Thalmann Buy $7.50
Jan-24-14Downgrade BMO Capital Markets Outperform → Market Perform $15
Jul-08-20 12:00PM  
Jun-29-20 08:51AM  
Jun-19-20 04:30AM  
Jun-14-20 09:47PM  
Jun-08-20 04:02PM  
Jun-03-20 09:53AM  
May-24-20 10:34PM  
May-20-20 07:58AM  
May-13-20 08:30AM  
May-10-20 10:53AM  
May-09-20 11:01PM  
May-07-20 04:02PM  
May-02-20 10:00AM  
Apr-30-20 12:33PM  
Apr-23-20 08:32AM  
Apr-15-20 04:02PM  
Apr-14-20 05:02PM  
Mar-24-20 08:31AM  
Mar-18-20 06:53AM  
Mar-16-20 05:15PM  
Mar-09-20 12:30PM  
Mar-03-20 04:02PM  
Feb-26-20 12:30PM  
Feb-18-20 08:30AM  
Feb-04-20 09:03AM  
Jan-08-20 04:02PM  
Jan-07-20 01:43AM  
Dec-23-19 07:31PM  
Dec-16-19 08:02AM  
Dec-12-19 09:05AM  
Dec-06-19 10:36AM  
Nov-28-19 02:29PM  
Nov-25-19 04:03PM  
Nov-14-19 04:05PM  
Nov-12-19 05:45PM  
Nov-05-19 10:33AM  
Oct-28-19 08:31AM  
Oct-18-19 10:23AM  
Oct-10-19 04:02PM  
Oct-07-19 03:27PM  
Oct-02-19 07:01AM  
Sep-27-19 02:54AM  
Sep-10-19 07:01AM  
Aug-28-19 08:31AM  
Aug-07-19 10:51AM  
Aug-02-19 10:24AM  
Aug-01-19 06:45PM  
Jul-29-19 07:01AM  
Jul-16-19 08:31AM  
Jun-28-19 06:40PM  
Jun-21-19 09:47AM  
May-13-19 08:31AM  
May-10-19 01:24PM  
May-09-19 06:15PM  
May-07-19 11:54AM  
Apr-25-19 08:01AM  
Mar-13-19 02:03AM  
Mar-07-19 01:19PM  
Mar-06-19 09:21PM  
Feb-19-19 08:31AM  
Feb-13-19 08:31AM  
Jan-25-19 02:02PM  
Jan-23-19 04:10PM  
Jan-22-19 08:31AM  
Jan-18-19 09:31AM  
Jan-17-19 04:01PM  
Jan-14-19 07:01AM  
Nov-16-18 08:35AM  
Nov-14-18 01:36AM  
Nov-07-18 04:01PM  
Oct-30-18 04:01PM  
Oct-24-18 08:31AM  
Oct-23-18 07:31AM  
Sep-17-18 08:31AM  
Aug-30-18 08:31AM  
Aug-26-18 11:55PM  
Aug-21-18 08:31AM  
Aug-09-18 04:01PM  
Jul-16-18 08:31AM  
Jul-09-18 08:31AM  
Jun-26-18 05:55PM  
Jun-25-18 09:01AM  
Jun-20-18 04:01PM  
Jun-19-18 04:01PM  
May-31-18 06:46AM  
May-30-18 07:02AM  
May-29-18 08:02AM  
May-24-18 07:02AM  
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-025, a fully canonized and affinity fusion protein targeting interleukin for the treatment of atopic dermatitis in dogs; KIND-032, caninized monoclonal antibody; and KIND-510a, a recombinant feline erythropoietin; and KIND-030, a chimeric and affinity monoclonal antibody targeting canine parvovirus. Further, it is developing KIND-509, an antibody for canine inflammatory bowel disease; KIND-511, an anti-tumor necrosis factor for the treatment of newborn foals; KIND-012, a dipyrone oral gel for the treatment of fever in horses; KIND-014 to treat gastric ulcers in horses; and epoCat, a feline recombinant erythropoietin for the management of anemia in cats. Additionally, it is developing KIND-015 for metabolic syndrome and anti-tumor necrosis factor for sick newborn foals; and interleukin antibodies and canine checkpoint inhibitors. The company was founded in 2012 and is headquartered in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Park West Asset Management LLC10% OwnerJun 26Sale4.71115,136542,2916,628,757Jun 30 09:30 PM